logo-loader
Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals concludes successful atopic dermatitis study

BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis.

a woman scratching her skin
Top line data indicates BTX 1204 was well-tolerated

Botanix Pharmaceuticals Ltd (ASX:BOT) has successfully completed a vehicle (placebo) controlled phase Ib study of BTX 1204 in patients with mild to moderate atopic dermatitis.

BTX 1204 is a novel topical formulation of synthetic cannabidiol that utilises Botanix’ proprietary drug delivery system Permetrex.

Twice as effective as the placebo

Top line data indicates BTX 1204 was well-tolerated as there were no significant adverse effects, or reports of skin irritation during the study.

Importantly, BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis after only four weeks of treatment

After four weeks of treatment, 35% of patients receiving BTX 1204 achieved treatment success, compared to only 18% of patients who received the vehicle.

Potential new treatment option for atopic dermatitis

About 18 to 25 million people in the United States suffer from atopic dermatitis, including between 8% to 18% of infants and children.

Atopic dermatitis has been considerably under-diagnosed due to the lack of approved effective systemic agents, and limitations of current topical agents.

Botanix executive director Matt Callahan said: “BTX 1204’s efficacy profile is in line with existing topical products whose treatment success rates are typically between 25-35%.

This combined with the excellent safety profile demonstrated to date underlines the potential for BTX 1204 to be a very safe and exciting new treatment for the millions of patients who suffer from this disease.”

Quick facts: Botanix Pharmaceuticals Ltd

Price: $0.25

Market: ASX
Market Cap: $241.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Blackstone Minerals PGE assays a game-changer at Vietnamese...

Blackstone Minerals Ltd (ASX:BSX) managing director Scott Williamson updates Proactive on its maiden drilling program at the Ta Khoa Nickel Project in northern Vietnam, which has delivered the project's first-ever PGE assays. Assay results from the first of three drill holes at Ta Khoa have...

1 hour, 49 minutes ago

2 min read